Ad
related to: GenzymeSee POMBILITI (cipaglucosidase alfa-atga) & OPFOLDA (miglustat) Safety, PI & Boxed Warning. Learn more about prescription treatment info and find helpful resources at our website.
- Healthcare Professionals
Information for physicians
and treaters
- Patient Support
Get support
from Amicus Assist
- Healthcare Professionals
Search results
Genzyme focuses on six areas of medicine relating to lysosomal storage diseases, renal disease, orthopedics, transplant and immune diseases, oncology, genetics and diagnostics. The first orphan-drug for Genzyme that FDA approved was Ceredase , a drug for treating Gaucher disease .
Feb 3, 2022 · Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...
Aug 6, 2015 · Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile. Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells.
People also ask
What does Genzyme do?
Is Genzyme a biotechnology company?
What drugs are made by Genzyme?
Is Genzyme a good treatment for Pompe disease?
Genzyme Corporation (Genzyme) is a biotechnology company. The Company's product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer,...
- Ceo
Apr 29, 2006 · Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has granted marketing approval for Myozyme® (alglucosidase alfa) in the United States. Myozyme has been approved for the treatment of patients with Pompe disease, a debilitating, progressive and often fatal disorder affecting fewer than 10,000 people worldwide.
Sep 9, 2020 · Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020 - New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system
Aug 6, 2021 · By MDA Staff | Friday, August 6, 2021. On Aug. 6, the US Food and Drug Administration (FDA) granted accelerated marketing approval to avalglucosidase alfa (Nexviazyme) for the treatment of people 1 year of age and older living with late-onset Pompe disease. It is the second approved drug to treat Pompe disease.
Ad
related to: GenzymeSee POMBILITI (cipaglucosidase alfa-atga) & OPFOLDA (miglustat) Safety, PI & Boxed Warning. Learn more about prescription treatment info and find helpful resources at our website.
